申请人:Novartis AG
公开号:US08193189B2
公开(公告)日:2012-06-05
The present invention relates to quinoxaline compound of the formula (I):
wherein
R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7;
R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8;
R3, R4, R5 and R6 are each independently hydrogen or R9; and
R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.
本发明涉及公式(I)的喹喔啉化合物:其中,R1是碳环或杂环,其中任意一个可以用1、2、3、4或5个R7取代;R2是碳环或杂环,其中任意一个可以用1、2、3、4或5个R8取代;R3、R4、R5和R6各自独立地是氢或R9;而R7、R8和R9各自独立地选自有机和无机取代基,它们用于治疗疾病,特别是由Janus激酶的酪氨酸激酶活性介导的疾病,包括JAK-2和JAK-3激酶。